Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 5
Submit an article Journal homepage
737
Views
148
CrossRef citations to date
0
Altmetric
Review

The benzodiazepine binding site of GABAA receptors as a target for the development of novel anxiolytics

John R AtackMerck Sharp & Dohme Research Laboratories Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QREnglandTel: +44 (0)1279 440494; Fax: +44 (0)1279 440390;E-mail: [email protected]
Pages 601-618 | Published online: 31 May 2005

Bibliography

  • ESTES JW: The road to tranquility: the search for selective anti-anxiety agents. Synapse (1995) 21:10–20.
  • ARGYROPOULOS SV, NUTT DJ: The use of benzodiazepines in anxiety and other disorders. Eur. Neuropsychopharmacol. (1999) 9\(Suppl. 6):S391–S392.
  • SHADER RI, GREENBLATT DJ: Use of benzodiazepines in anxiety disorders. N Engl. J. Med. (1993) 328:1398–1405.
  • GORMAN JM: Treating generalized anxiety disorder. J. Clin. Psychiatry (2003) 64\(Suppl. 2):24–29.
  • WOODS JH, WINGER G: Current benzodiazepine issues. Psychopharmacol (1995) 118:107–115.
  • •Review of issues associated with the abuse and physical dependence liabilities of BZs.
  • BUFFET-JERROTT SE, STEWART SH: Cognitive and sedative effects of benzodiazepine use. Curr. Pharm. Des. (2002) 8:45–58.
  • CUMMING RG, LE COUTER DG: Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs (2003) 17:825–837.
  • SCHWEIZER E, RICKELS K: Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr. Scand. Suppl. 1998(1998) 393:95–101.
  • CHOUINARD G: Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. j. Clin. Psychiatry (2004) 65 (Suppl. 5):7–12.
  • FRICCHIONE G: Clinical practice. Generalized anxiety disorder. N Engl. Med. (2004) 351:675–682.
  • ASHTON H: Benzodiazepine abuse. In: Drink, Drugs and Dependence - From Science to Clinical Practice. Caan W, de Belleroche J (Eds) London, UK (2002):197–211.
  • ROBERTSON JR, TREASURE W: Benzodiazepine abuse - nature and extent of the problem. CNS Drugs (1996) 5:137–146.
  • WOODS JH: Problems and opportunities in regulation of benzodiazepines. ./. Clin. Pharmacol (1998) 38:773–782.
  • WOODS JH, WINGER G: Abuse liability of flunitrazepam.j. Cliii. Psychopharmacol (1997) 17\(Suppl. 2):1S–575.
  • GRIFFITHS RR, WOLF B: Relative abuse liability of different benzodiazepines in drug abusers. ./. Cliii. Psychopharmacol (1990) 10:237–243.
  • WEINTRAUB M, SINGH S, BYRNE L, MAHARAJ K, GUTTMACHER L: Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. I Am. Med. Assoc. (1991) 266:2392–2397.
  • UHLENHUTH EH, BALTER MB, BAN TA, YANG K: International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders. J. Clin.Psychopharmacol. (1999) 19\(Suppl. 2):23S–29S.
  • UHLENHUTH EH, BALTER MB, BAN TA, YANG K: Trends in recommendations for the pharmacotherapy of anxiety disorders by an international expert panel, 1992–1997. Eur. Neuropsychopharmacol. (1999) 9\(Suppl. 6):S393–S398.
  • COSTA E, GUIDOTTI A, MAO CC: Evidence for involvement of GABA in the action of benzodiazepines: studies on rat cerebellum. Adv. Biochem. Psychopharmacol (1975) 14:113–130.
  • HAEFELY W, KULCSAR A, MOHLER H, PIERI L, POLC P, SCHAFFNER R: Possible involvement of GABA in the central actions of benzodiazepines. Adv. Biochem. Psychopharmacol. (1975) 14:131–151.
  • CHOI DW, FARB DH, FISCHBACH GD: Chlordiazepoxide selectively augments GABA action in spinal cord cell cultures. Nature (1977) 269:342–344.
  • BRAESTRUP C, SQUIRES RF: Specific benzodiazepine receptors in rat brain characterized by high-affinity 3H-diazepam binding. Proc. Nati Acad. Sci. USA (1977) 74:3805–3809.
  • MOHLER H, OKADA T: Properties of PHI diazepam binding to benzodiazepine receptors in rat cerebral cortex. Life Sci. (1977) 20:2101–2110.
  • MOHLER H, OKADA T: The benzodiazepine receptor in normal and pathological human brain. BE I Psychiatry (1978) 133:261–278.
  • TALLMAN JF, GALLAGHER DW: The GABA-ergic system: a locus of benzodiazepine action. Ann. Rev Neurosci. (1985) 8:21–44.
  • HILL DR, BOWERY NG: 3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABAB sites in rat brain. Nature (1981) 290:149–152.
  • KLEPNER CA, LIPPA AS, BENSON DI, SANO MC, BEER B: Resolution of two biochemically and pharmacologically distinct benzodiazepine receptors. Pharmacol Biochem. Behav. (1979) 11:457–462.
  • SQUIRES RF, BENSON DI, BRAESTRUP C et al.: Some properties of brain specific benzodiazepine receptors: New evidence for multiple receptors. Pharmacol Biochem. Behav. (1979) 10:825–830.
  • BRAESTRUP C, NIELSON M: PHIPropy113-carboline-3-carboxylate as a selective ligand for the BZ1 benzodiazepine receptor subclass. J. Neurochem. (1981) 37:333–341.
  • SIEGHART W, SCHUSTER A: Affinity ofvarious ligands for benzodiazepine receptors in rat cerebellum and hippocampus. Biochem. Pharmacol (1984) 33:4033–4038.
  • SIGEL E, BARNARD EA: A y-aminobutyric acidibenzodiazepine receptor complex from bovine cerebral cortex. Improved purification with preservation of regulatory sites and their interactions. J. Biol Chem. (1984) 259:7219–7223.
  • SCHOFIELD PR, DARLISON MG, FUJITA N et al: Sequence and functional expression of the GABAA receptor shows a ligand-gated receptor super-family. Nature (1987) 328:221–227.
  • LEVITAN ES, SCHOFIELD PR, BART DR et al.: Structural and functional basis for GABAA receptor heterogeneity. Nature (1988) 335:76–79.
  • PRITCHETT DB, LUDDENS H, SEEBURG PH: Type I and type II GABAA-benzodiazepine receptors produced in transfected cells. Science (1989) 245:1389–1392.
  • BARNARD EA, SKOLNICK P, OLSEN RW et al.: International Union of Pharmacology. XV. Subtypes of y-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev (1998) 50:291–313.
  • •Review of the classification and nomenclature of GABAA receptors.
  • CROMER BA, MORTON CJ, PARKER MW: Anxiety over GABAA receptor structure relieved by AChBP. Trends Biochem. Li. (2002) 27:280–287.
  • SIMON J, WAKIMOTO H, FUJITA N, LALANDE M, BARNARD EA: Analysis of the set of GABAA receptor genes in the human genome. I Biol. Chem. (2004) 279:41422–41435.
  • BORMAN J: The 'ABC of GABA receptors. Trends Pharmacol Li. (2000) 21:16–19.
  • McKERNAN RIVI, WHITING PJ: Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci. (1996) 19:139–143.
  • SIEGHART W, SPERK G: Subunit composition, distribution and function of GABAA receptor subtypes. Curr. Top. Med. Chem. (2002) 2:795–816.
  • MINIER F, SIGEL E: Techniques: use of concatenated subunits for the study of ligand-gated ion channels. Trends Pharmacol Sci. (2004) 25:499–503.
  • SIEGHART W: Structure and pharmacology of y-aminobutyric acidA receptor subtypes. Pharmacol Rev (1995) 47:181–234.
  • ••Detailed review of the pharmacology of thenumerous binding sites on the GABAA receptors.
  • PRITCHETT DB, SEEBURG PH: y-aminobutyric acidA receptor a5-subunit creates novel type II benzodiazepine receptor pharmacology. J. Neurochem. (1990) 54:1802–1804.
  • WISDEN W, HERB A, WEILAND H, KEINAN K, LUDDENS H, SEEBURG PH: Cloning, pharmacological characteristics and expression pattern of rat GABAA receptor a4 subunit. FEBS Lett (1991) 289:227–230.
  • WIELAND HA, LUDDENS H, SEEBURG PH: A single histidine in GABAA receptors is essential for benzodiazepine agonist binding. J. Biol. Chem. (1992) 267:1426–1429.
  • •Original description of how a single histidine residue determines the binding of diazepam to al-,112 a3- and a5- but not a4- or a6-containing GABAA.
  • BENSON JA, LOW K, KEIST R, MOHLER H, RUDOLPH U: Pharmacology of recombinant y-aminobutyric acidA receptors rendered diazepam-insensitive by point-mutated a-subunits. FEBS Lett (1998) 431:400–404.
  • ••Characterisation of recombinant GABAAreceptors containing point mutated a-subunits and recognition of the Importance of key histidine residue in not only determining affmity of diazepam, but also the efficacy of other ligands such as bretazenil and Ro-15–4513. Also, description of potential in vivo uses of point-mutated a-subunits.
  • RUDOLPH U, MOHLER H: Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. AMU. Rev Pharmacol Toxicol. (2004) 44:475–498.
  • MOROZ G: High-potency••benzodiazepines: recent clinical results. Clin. Psychiatry (2004)65 (Suppl. 5):13–18.
  • HUNKELER W, MOHLER H, PIERI L59.et al.: Selective antagonists of benzodiazepines. Nature (1981)290:514–516.
  • WISDEN W, LAURIE DJ, MONYER H, SEEBURG PH: The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. Neurosci. (1992) 12:1040–1062.
  • FRITSCHY J-M, MOHLER H: GABAA receptor heterogeneity in the adult rat brain: Differential regional and cellular distribution of seven major subunits. J. Comp. Neurol (1995) 359:154–194.
  • SPERK G, SCHWARZER C, TSUNASHIMA K, FUCHS K, SEIGHART W: GABAA receptor subunits in the rat hippocampus: I. Immuncytochemical distribution of 13 subunits. Neuroscience (1997) 80:987–1000.
  • PIRKER S, SCHWARZER C, WIESELTHALER A, SIEGHART W, SPERK G: GABAA receptors: Immunocytochemical distribution of 13 subunits in the adult brain. Neurosci. (2000) 101:815–850.
  • ROSAHL TW: Validation of GABAA receptor subtypes as potential drug targets by using genetically modified mice. Curr. Drug Targets - CNS Neurol Dis. (2003) 2:53–59.
  • BOEHM II SL, PONOMAREY I, JENNINGS AW et al: y-Aminobutyric acidA receptor subunit mutant mice: new perspectives on alcohol actions. Biochem. Pharmacol (2004) 68:1581–1602.
  • CRESTANI F, ASSANDRI R, TAUBER M, MARTIN JR, RUDOLPH U: Contribution of the al-GABAA receptor subtype to the pharmacological actions of benzodiazepine site inverse agonists. Neuropharmacology (2002) 43:679–684.
  • KOPP C, RUDOLPH U, TOBLER I: Sleep EEG changes after zolpidem in mice. Neuroreport (2004) 15:2299–2302.
  • RUDOLPH U, CRESTANI F, BENKE D et al.: Benzodiazepine actions mediated by specific y-aminobutyric acidA receptor subtypes. Nature (1999) 401:796–800.
  • •• Initial description of the in vivo use of point-mutated al-subunit (H101R) to establish the role of al-containing GABAA receptors in sedative effects of diazepam.
  • McKERNAN RM, ROSAHL TW, REYNOLDS DS et al: Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor ai subtype. Nat. Neurosci. (2000) 3:587-592. Confirmation of the importance of the al-subunit in mediating sedative effects of diazepam using a1-H101R mice. Also, first description of the prototypic, efficacy selective compound L-838417 and its non-sedating anxiolytic properties in rodents.
  • LOW K, CRESTANI F, KEIST R et al: Molecular and neuronal substrate for the selective attenuation of anxiety. Science (2000) 290:131–134.
  • ••Use of a2-H101R and a3-H126R point-mutated mice to demonstrate the role of a2-containing GABAA receptors in determining anxiolytic efficacy of diazepam.
  • CRESTANI F, LOW K, KEIST R, MANDELLI M-J, MOHLER H, RUDOLPH U: Molecular targets for the myorelaxant action of diazepam. Mol. Pharmacol. (2001) 59:442–445.
  • TOBLER I, KOPP C, DEBOER T, RUDOLPH U: Diazepam-induced changes in sleep: role of the al GABAA receptor subtype. Proc. Natl. Acad. Li. USA (2001) 98:6464–6469.
  • KOPP C, RUDOLPH U, KEIST R, TOBLER I: Diazepam-induced changes on sleep and the EEG spectrum in mice: role of the a3-GABAA receptor subtype. Eur. Neurasci. (2003) 17:2226–2230.
  • CRESTANI F, KEIST R, FRITSCHY J-M et al: Trace fear conditioning involves hippocampal a5 GABAA receptors. Proc. Nati Acad. Sci. USA (2002) 99:8980–8985.
  • •Generation of a5H105R point-mutated mice resulted in decreased hippocampal expression of a5-containing GABAA receptors. As a result, mice had altered trace fear conditioning, suggesting a role for this receptor subtype in cognition.
  • COLLINSON N, KUENZI FM, JAROLIMEK W et al.: Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the a5 subunit of the GABAA receptor. Neurosci. (2002) 22:5572–5580.
  • CHAMBERS MS, ATACK JR, CARLING RW et al: An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA a5 receptors with cognition enhancing properties. J. Med. Chem. (2004) 47:5829–5832.
  • STERNFELD F, CARLING RW, JELLEY RA et al.: Selective, orally active y-aminobutyric acidA 15 receptor inverse agonists as cognition enhancers. J. Med. Chem. (2004) 47:2176–2179.
  • STREET LJ, STERNFELD F, JELLEY RAet al.: Synthesis and biological evaluation of 3-heterocycly1-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo13,4-alphthalazines and analogues as subtype-selective inverse agonists for the GABAA a5 benzodiazepine binding site. J. Med. Chem. (2004) 47:3642–3657.
  • ATACK JR, HUTS ON PH, COLLINSON N et al: Anxiogenic properties of an inverse agonist selective for a3 subunit-containing GABAA receptors. BE J. Pharmacol (2005) 144:357–366.
  • •Description of the anxiogenic properties of an a3-selective inverse agonist.
  • LE DOUX JE: Emotion circuits in the brain. Ann. Rev Neurasci. (2000) 23:155–184.
  • WALKER DL, TOUFEXIS DJ, DAVIS M: Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur..I. Pharmacol (2003) 463:199–216.
  • HAEFELY W, MARTIN JR, SCHOCH P: Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol Li. (1990) 11:452–456.
  • •Detailed discussion of the potential advantages of BZ site partial agonists compared to full agonists.
  • COSTA E, GUIDOTTI A: Benzodiazepines on trial: a research strategy for their rehabilitation. Trends Pharmacol Li. (1996) 17:192–200.
  • ATACK JR: Anxioselective compounds acting at the GABAA receptor benzodiazepine binding site. Curr. Drug Targets - CNS Neurol Disorders (2003) 2:213–232.
  • GIUSTI P, DUCIC I, PUIA G et al: Imidazenil: A new partial positive allosteric modulator of y-aminobutyric acid (GABA) action at GABAA receptors. J. Pharmacol Expt. Therap. (1993) 266:1018–1028.
  • COSTA E: From GABAA receptor diversity emerges a unified vision of GABAergic inhibition. AMU. Rev Pharmacol Toxicol (1998) 38:321–350.
  • JENSEN ML, TIMMERMANN DB, VARMING T, JOHANSEN TH, AHRING PK: Two distinct actions of the novel anxiolytic compound NS 2710 on GABAA receptors. Soc. Neurosci. Abstr. (2001) 491:8.
  • MIRZA NR, NIELSEN EO, JOHANSEN TH et al: N52664: An atypical benzodiazepine site ligand. 2003 Abstract Viewer/Itinerary Planner. Society for Neuroscience Washington DC. (2003) 959:8.
  • SMITH AJ, ALDER L, SILK J et al: Effect of a subunit on allosteric modulation of ion channel function in stably expressed human recombinant y-aminobutyric acidA receptors determined using 36C1 ion flux. Mot. Pharmacol (2001) 59:1108–1118.
  • FLECK MW: Molecular actions of (V-desmethylzopiclone (SEP-174559), an anxiolytic metabolite of zopiclone. Pharmacol Exp. Therap. (2002) 302:612–618.
  • CARLSON JN, HASKEW R, WACKER J, MAISONNEUVE IM, GLICK SD, JERUSSI TP: Sedative and anxiolytic effects of zopiclone's enantiomers and metabolite. Eur.j Pharmacol (2001) 415:181–189.
  • McMAHON LR, JERUSSI TP, FRANCE CP: Stereoselective discriminative stimulus effects of zopiclone in rhesus monkeys. Psychopharmacol (2003) 165:222–228.
  • DUBINSKY B, VAIDYA AH, ROSENTHAL DI et al: 5-Ethoxymethy1-7-fluoro-3-oxo-1,2,3,5- tetrahydrobenzo, 5Iimidazo [1, 2a]pyridine -4-N-(2-fluoropheny6carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic. I Pharmacol Expt. Therap. (2002) 303:777–790.
  • GARDNER CR, DEACON R, GUY AP, MANN G, BUDHRAM P, MILLER P: RU 32698, a new benzodiazepine receptor ligand with anxiolytic but little sedative/ myorelaxant properties. BE J. Pharmacol (1987) 92:537P.
  • ADIS: Y 23684. Drugs R D (1999) 2:68–69.
  • ZONG WZ, WILLIAMS MG, BRANSTETTER DG: Toxicokinetics in drug development: an overview of toxicokinetic application in the development of PNU-101017, an anxiolytic drug candidate. Curr. Drug Metab. (2000) 1:243–254.
  • ULRICH RG, BACON JA, BRANSTETTER DG et al.: Induction of a hepatic toxic syndrome in the Dutch-belted rabbit by a quinoxalinone anxiolytic. Toxicology (1995) 98:187–198.
  • ULRICH RG, BACON JA, BRASS EP, CRAMER CT, PETRELA DK, SUN EL: Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon. Chem. Biol. Interact. (2001) 134.251–270.
  • VAN STEVENINCK AL, GIESCHKE R, SCHOEMAKER RC et al.: Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. BE J. Clia PharmacoL (1996) 41:565–573.
  • DELINI-STULA A, BERDAH-TORDJMAN D: Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia-a study group report. Psychiatr. Res. (1996) 30:239–250.
  • EVANS SM, FOLTIN RW, LEVIN FR, FISCHMAN MW: Behavioral and subjective effects of DN-2327 (pazinaclone) and alprazolam in normal volunteers. Behav. Pharmacol (1995) 6:176–186.
  • LINDEN M, HADLER D, HOFMAN S: Randomised, double-blind, placebo-controlled trial of the efficacy and tolerability of a new isoindoline derivative (DN-2327) in generalized anxiety. Hum. Psychopharmacol Clia Exper. (1997) 12:445–452.
  • MUMFORD GK, RUSH CR, GRIFFITHS RR: Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. ./. Pharmacol Expt. Therap. (1995) 272:570–80.
  • LYDIARD RB, BALLENGER JC, RICKELS K: A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J. Clin. Psychiatry (1997) 58\(Suppl. 11):11–18.
  • POLLACK MH, WORTHINGTON JJ, MANFRO GG, OTTO MW, ZUCKER BG: Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. I Clin. Psychiatry (1997) 58\(Suppl. 11):19–23.
  • AUFDEMBRINKE B: Abecarnil, a new 13-carboline, in the treatment of anxiety disorders. Br. J. Psychiatry (1998) 173\(Suppl. 34):55–63.
  • RICKELS K, DeMARTINIS N, AUFDEMBRINKE B: A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder. J. Psychopharmacol (2000) 20:12–18.
  • QUIRK K, BLURTON P, FLETCHER S et al: PHIL-655,708, A novel ligand selective for the benzodiazepine site of GABAA receptors which contain the a5 subunit. Neuropharmacology (1996) 35:1331–1335.
  • SKOLNICK P, HU RJ, COOK CM et al:PHIRY 80: A high-affinity, selective ligand for y-aminobutyric acidA receptors containing a5-subunits. I Pharmacol Exp. Therap. (1997) 283:488–493.
  • MARTIN IL, LATTMAN E: Benzodiazepine recognition site ligands and GABAA receptors. Expert Opin. Ther. Patents (1999) 9:1347–1358.
  • COOKE AJ, HAMILTON NM: a-Subunit selective modulators of GABAA receptor function as CNS therapeutics. Expert Opin. Ther. Patents (2002) 2:1491–1501.
  • COLLINS IJ, MOYES CR, DAVEY WB et al.: 3-Heteroary1-2-pyridones: Benzodiazepine site agonists with functional selectivity for a2/a3-subtypes of human GABAA receptor-ion channels. I Med. Chem. (2002) 45:1887–1900.
  • CHAMBERS MS, ATACK JR, BROMIDGE FA et al: 6,7-Dihydro-2-benzothiophen-4(5H)-ones: a novel class of GABAA a5 receptor inverse agonists. [Med. Chem. (2002) 45:1176–1179.
  • CHAMBERS MS, ATACK JR, BROUGHTON HB et al: Identification of a novel, selective GABAA a5 receptor inverse agonist which enhances cognition. J. Med. Chem. (2003) 46:2227–2240.
  • SZEKERES HJ, ATACK JR, CHAMBERS MS et al: 3,4- Dihydronaphthalen-1 (2H)-ones: novel ligands for the benzodiazepine site of a5-containing GABAA receptors. Bioorg. Med. Chem. Lett. (2004) 14:2871–2875.
  • JOHNSTONE TB, HOGENKEMP DJ, COYNE L et al.: Modifying quinolone antibiotics yields new anxiolytics. Nature Med. (2004) 10:31–32.
  • MIRZA NR, SANDAGER NIELSEN K, HARTZ B, MATHIESON L, AHRING PK: An in-vivo method for differentiating subtype-selective and non-selective GABAA receptor positive modulators. FENS Abstr. (2004) 2:A164:13.
  • ROWLETT JK, PLATT DM, LELAS S, ATACK JR, DAWSON GR: Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc. Natl. Acad. Sci. USA (2005) 102:915–920.
  • •Confirmation that the non-sedating anxiolytic properties of L-838417 initially observed in rodents extends to primates.
  • ROSTOCK A, TOBER C, DOST R et al: AWD-131-138. Drugs Future (1998) 23:253–255.
  • MEALY NE, BAYES M: Treatment of psychiatric disorders. Drugs Fut. (2004) 29:923–977.
  • GRIEBEL G, PERRAULT G, SIMIAND J et at: SL651498: an anxioselective compound with functional selectivity for a2- and a3-containing y-aminobutyric acidA (GABAA) receptors. J. Phannacol Expt. Therap. (2001) 298:753–768.
  • GRIEBEL G, PERRAULT G, SIMIAND J et al: SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for Generalized Anxiety Disorder and muscle spasms. CNS Drug Rev. (2003) 9:3–20.
  • DOBLE A, CANTON T, DRIESLER S, PIOT 0 et al: RP 59037 and RP 60503: anxiolytic cyclopyrrolone derivatives with low sedative potential. interaction with the y-aminobutyric acidA/benzodiazepine receptor complex and behavioral effects in the rodent. I Phannacol Exp. Therap. (1993) 266:1213–1226.
  • BATESON A: Pagoclone Indevus. Curr. Opin. Investig. Drugs (2003) 4:91–95.
  • ATACK JR, PIKE A, MARSHALL G et al: The in vivo properties of pagoclone in rat are mediated by the hydroxylated metabolite. 2004 Abstract viewer/Itinerary Planner, Society for Neuroscience, Washington D.C. (2004) 844:9.
  • LINGFORD-HUGHES AR, UHL N, FEENEY AJ et al.: Is pagoclone a partial agonist at the central GABA-benzodiazepine receptor: a PIC] flumazenil positron emission tomography study? Int. Neuropsychopharmacol. (2000) 3\(Suppl. 1):5288.
  • SANDFORD JJ, FORSHALL S, BELL C et al Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. J. Psychophannacol (2001) 15:205–208.
  • SORBERA LA, LEESON PA, SILVESTRE J, CASTANER J: Pagoclone. Drugs Fut. (2001) 26:651–657.
  • KAVOUSSI RJ, PANDE AC, LYDIARD RB, PAPP L, PIGOTT TA, RICKELS K: Efficacy and safety of pagoclone, a novel GABA modulator in the treatment of panic disorder with or without agoraphobia. Int. I Neuropsychophannacol (2000) 3\(Suppl. 1):5280.
  • VANOVER KE, ZHANG L, BARRETT JE: Discriminative stimulus and anxiolytic-like effects of the novel compound CL 273,547. Exp. Chit Psychophannacol (1994) 2:223–233.
  • KOSTAKIS EE, GRAVIELLE MC, SKOLNICK P et al.: Subtype selective modulation of GABAA receptor by ocinaplon, an anxioselective pyrazolopyrimidine. Abstract Viewer/ Itinerary Planner. Sono, for Neuroscience, 2003, Washington DC (2003) 48.3.
  • BEER B, CZOBOR P, LIPPA A, PETTI S, SKOLNICK P, STARK J: Efficacy of Ocinaplon, a novel GABAA receptor modulator, in Generalized Anxiety Disorder. Abstract Viewer/Itinerary Planner. Society for Neuroscience, 2002, Washington DC (2002) 396:15.
  • CHILMAN-BLAIR K, CASTANER J, SILVESTRE JS: Ocinaplon. Drugs Future (2003) 28:115–120.
  • CZOBOR P, STARK J, BEER G et al: A double-blind, placebo controlled study of DOV 273,547 (ocinaplon) in the treatment of generalized anxiety disorder (GAD). Abstract Viewer/Itinerary Planner. Society for Neuroscience, 2003, Washington DC (2003) 959.12.
  • LEWIS DA, VOLK DW, HASHIMOTO T: Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychophannacology (Berl.) (2004) 174:143–150.

Websites

  • http://www.Sepraconcom Sepracor Press release, January 27 2005,
  • hdp://www.Neurosearch.com Neurosearch Press release, 22 March 2002.
  • http://www.Sepraconcom Sepracor Press release, October 26 2004.
  • http://www.Dovpharm.com DOV Pharmaceutical web site (2005).
  • http://en.sanofi-aventis.com2004 Full-Year Results - Analysis/Investors Meeting, Paris, France, March 1 2005.
  • http://www.Elbion.de Elbion website.
  • http://www.Neurogen.com Neurogen Press release, December 20 2001.
  • http://www.Indevus.com Indevus 2004 annual report (2005).
  • http://en.sanofi-aventis.com Sanofi-Aventis Banque Pictet European Healthcare Conference, New York, April 30 2004.
  • http://www.Indevus.com Interneuron Press release, December 19 2001.
  • http://www.Indevus.com Indevus: Press release, June 6 2002.
  • http://www.Dovpharm.com DOV Press release, November 23 2004.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.